Immunotherapy combo shows promise in tough breast cancer
NCT ID NCT04085276
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 3 trial tested whether adding the immunotherapy drug toripalimab to standard chemotherapy (nab-paclitaxel) helps people with metastatic or recurrent triple-negative breast cancer live longer without their cancer growing. The study included 531 participants and compared the combination to chemotherapy alone. The main goal was to see if the combination delays cancer progression, especially in patients whose tumors have a specific marker (PD-L1).
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Toripalimab (an immunotherapy drug) combined with nab-paclitaxel (a chemotherapy drug)
What this could lead to
If successful, this combination could offer a new treatment option that slows cancer growth in people with metastatic triple-negative breast cancer.
What could go wrong
This is a completed phase 3 trial, but results are not yet widely available. Immunotherapy can cause immune-related side effects, and not all patients may benefit.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TRIPLE NEGATIVE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Affiliated Hospital of Chengde Medical University
Chengde, China
-
Affiliated Hospital of Hebei University
Baoding, China
-
Affiliated Hospital of Jiangnan University（Wuxi NO.4 People's Hospital）
Wuxi, China
-
Anhui Province Hospital & The First Affiliated Hospital of USTC
Hefei, China
-
Beijing Hospital
Beijing, Beijing Municipality, China
-
Cancer Hospital Affiliated to Xinjiang Medical University
Ürümqi, China
-
Changhai Hospital
Shanghai, China
-
Chinese PLA General Hospital
Beijing, Beijing Municipality, China
-
Chongqing Cancer Hospital
Chongqing, China
-
Fujian Medical University Union Hospital
Fuzhou, China
-
General Hospital of Ningxia Medical University
Yinchuan, China
-
Guangdong General Hospital
Guangzhou, China
-
Harbin Medical University Cancer Hospital
Harbin, China
-
Henan Cancer Hospital
Zhengzhou, China
-
Henan Provincial People's Hospital
Zheng'zhou, China
-
Hubei Cancer Hospital
Wuhan, China
-
Hunan Cancer Hospital
Changsha, China
-
Jiangsu Cancer Hospital
Nanjing, China
-
Jiangsu Province Hospital
Nanjing, China
-
Jiangxi Cancer Hospital
Nanchang, China
-
Jilin Cancer Hospital
Changchun, China
-
Liaoning Cancer Hospital&Intitute
Shenyang, China
-
Linyi Cancer Hospital
Linyi, China
-
Peking University Shougang Hospital
Beijing, Beijing Municipality, China
-
Shandong Cancer Hospital
Jinan, China
-
Shanghai General Hospital
Shanghai, China
-
Sichuan Cancer Hospital
Chengdu, China
-
Sun Yat-sen Memorial Hospital, Sun Yat-sen University
Guangzhou, China
-
Sun Yat-sen University Cancer Center
Guangzhou, China
-
The Affiliated Hospita of Inner Mongolia Medical University
Hohhot, China
-
The Affiliated Hospita of of Southwest Medical University
Luzhou, China
-
The Affiliated Hospital of Qingdao University
Qingdao, China
-
The Fifth Medical Center of PLA General Hospital
Beijing, Beijing Municipality, 100071, China
-
The First Affiliated Hospital Zhejiang University
Hangzhou, China
-
The First Affiliated Hospital of Anhui Medical University
Hefei, China
-
The First Affiliated Hospital of Nanchang University
Nanchang, China
-
The First Affiliated Hospital of Xi'an Jiaotong University
Xi'an, China
-
The First Affiliated Hospital of Xiamen University
Xiamen, China
-
The First Affiliated Hospital, Sun Yat-sen University
Guangzhou, China
-
The First Hospital of China Medical University
Shenyang, China
-
The First Hospital of Jilin University
Changchun, China
-
The First People's Hospital of Foshan
Foshan, China
-
The Fourth Hospital of Hebei Medical University
Shijiazhuang, China
-
The Second Affiliated Hospital of The PLA Air Force Military Medical University
Xi'an, China
-
The Second Affiliated Hospital of Zhejiang University School of Medicine
Hangzhou, China
-
The Second Hospital of Anhui Medical University
Hefei, China
-
The Second Hospital of Dalian Medical University
Dalian, China
-
The Third Hospital of Nanchang
Nanchang, China
-
The Women and Children's Hospital of Guangdong Province
Guangzhou, China
-
The first affiliated Hospital of Bengbu Medical College
Bengbu, China
-
Tongji Hospital Tongji Medical College Huazhong University of Science and Technology
Wuhan, China
-
Union Hospital Tongji Medical College Huazhong University of Science and Technology
Wuhan, China
-
Xiangyang Central Hospital
Xiangyang, China
-
Yunnan Cancer Hospital
Kunming, China
-
Zhejiang Cancer Hospital
Hangzhou, China